Skip to Content
Søk Menu

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

Results from the AVENANCE trial suggest that avelumab may provide a promising maintenance treatment option for patients with low-burden urothelial carcinoma, showing encouraging survival and progression-free survival outcomes after chemotherapy.
Philippe Barthélémy

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Njurcancer
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blåscancer Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatacancer

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blåscancer

Efficacy of 1L Treatment Does Not Predict Efficacy of 2L Cabozantinib for Patients with mRCC

/ Martin Zarba / Jan Andreasen
ASCOGU25Njurcancer

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Jan Andreasen
ASCOGU25Njurcancer
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlåscancerTyp 2-diabetes Play the Video 02:42
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blåscancer Play the Video 06:12
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostatacancer Play the Video 09:06
Back to top